[Recent advances in the treatment of antineutrophil cytoplasm antibody associated vasculitides]. / Antineutrofil citoplazmatikus antitest asszociált vasculitisek korszeru kezelése.
Orv Hetil
; 156(41): 1653-60, 2015 Oct 11.
Article
en Hu
| MEDLINE
| ID: mdl-26551168
The authors review the nomenclature of vasculitides and the classification of antineutrophil cytoplasm antibody associated vasculitides and present the method of measuring disease activity (Five-factor Score, Birmingham Vasculitis Activity Score) and its role in defining therapeutical needs. They discuss the treatment algorithm of antineutrophil cytoplasm antibody associated vasculitides, present the sometimes equipotential medications used during the induction therapy followed by a maintenance regimen, and outline their usage and possible side-effects that may require medical attention. They point out the importance of plasmapheresis as an adjunctive treatment in some cases, as well as indications and possible outcome of kidney transplantation in therapy-resistant cases. Finally, they review several ongoing clinical studies, as their outcome will probably influence therapeutical opportunities of antineutrophil cytoplasm antibody associated vasculitides in the next few years.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos
/
Inmunosupresores
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
Hu
Revista:
Orv Hetil
Año:
2015
Tipo del documento:
Article
Pais de publicación:
Hungria